NZ703597A - Mutant fragments of ospa and methods and uses relating thereto - Google Patents

Mutant fragments of ospa and methods and uses relating thereto

Info

Publication number
NZ703597A
NZ703597A NZ703597A NZ70359713A NZ703597A NZ 703597 A NZ703597 A NZ 703597A NZ 703597 A NZ703597 A NZ 703597A NZ 70359713 A NZ70359713 A NZ 70359713A NZ 703597 A NZ703597 A NZ 703597A
Authority
NZ
New Zealand
Prior art keywords
ospa
methods
mutant fragments
uses relating
polypeptide
Prior art date
Application number
NZ703597A
Other languages
English (en)
Inventor
Pär Comstedt
Urban Lundberg
Andreas Meinke
Markus Hanner
Wolfgang Schüler
Benjamin Wizel
Christoph Reinisch
Brigitte Grohmann
Robert Schlegl
Original Assignee
Valneva Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valneva Austria Gmbh filed Critical Valneva Austria Gmbh
Priority to NZ73302613A priority Critical patent/NZ733026A/en
Publication of NZ703597A publication Critical patent/NZ703597A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1207—Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NZ703597A 2012-07-06 2013-07-08 Mutant fragments of ospa and methods and uses relating thereto NZ703597A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ73302613A NZ733026A (en) 2012-07-06 2013-07-08 Mutant fragments of ospa and methods and uses relating thereto

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261668627P 2012-07-06 2012-07-06
US13/802,991 US8986704B2 (en) 2012-07-06 2013-03-14 Mutant fragments of OspA and methods and uses relating thereto
PCT/EP2013/064403 WO2014006226A1 (en) 2012-07-06 2013-07-08 MUTANT FRAGMENTS OF OspA AND METHODS AND USES RELATING THERETO

Publications (1)

Publication Number Publication Date
NZ703597A true NZ703597A (en) 2017-06-30

Family

ID=49878705

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ703597A NZ703597A (en) 2012-07-06 2013-07-08 Mutant fragments of ospa and methods and uses relating thereto
NZ73302613A NZ733026A (en) 2012-07-06 2013-07-08 Mutant fragments of ospa and methods and uses relating thereto

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ73302613A NZ733026A (en) 2012-07-06 2013-07-08 Mutant fragments of ospa and methods and uses relating thereto

Country Status (24)

Country Link
US (9) US8986704B2 (https=)
EP (3) EP3360568B1 (https=)
JP (1) JP6276258B2 (https=)
KR (2) KR102190981B1 (https=)
CN (2) CN107602676B (https=)
AU (2) AU2013285364B2 (https=)
CA (1) CA2876541C (https=)
CY (1) CY1120772T1 (https=)
DK (1) DK2869839T3 (https=)
EA (2) EA033007B1 (https=)
ES (2) ES2688883T3 (https=)
HR (1) HRP20181689T1 (https=)
HU (1) HUE041286T2 (https=)
LT (1) LT2869839T (https=)
MX (2) MX391136B (https=)
NZ (2) NZ703597A (https=)
PL (1) PL2869839T3 (https=)
PT (1) PT2869839T (https=)
RS (1) RS57847B1 (https=)
SI (1) SI2869839T1 (https=)
SM (1) SMT201800557T1 (https=)
TR (1) TR201815419T4 (https=)
WO (1) WO2014006226A1 (https=)
ZA (1) ZA201409222B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
HUE043779T2 (hu) * 2014-01-09 2019-09-30 Valneva Austria Gmbh Az OspA mutáns fragmensei, valamint az ezzel kapcsolatos módszerek és alkalmazások
RU2689315C2 (ru) * 2014-06-27 2019-05-27 Убе Индастриз, Лтд. Соль гетероциклического соединения, замещенного галогеном
WO2016022958A2 (en) * 2014-08-07 2016-02-11 The Trustees Of Columbia University In The City Of New York Tick-associated virus sequences and uses thereof
US11197826B2 (en) * 2015-12-23 2021-12-14 Novartis Ag Oil-in-water emulsions including retinoic acid
WO2017139715A1 (en) * 2016-02-11 2017-08-17 The Translational Genomics Research Institute Systems and methods for the detection of infectious diseases
US12018054B2 (en) 2017-04-13 2024-06-25 Valneva Austria Gmbh Multivalent OspA polypeptides and methods and uses relating thereto
KR20190001421U (ko) 2019-05-26 2019-06-13 이준형 노크형 내부 수납식 칫솔
CN110483624B (zh) * 2019-08-22 2021-02-09 中国疾病预防控制中心传染病预防控制所 伽氏疏螺旋体OspA蛋白C端肽段及其应用
CN111269919B (zh) * 2020-03-19 2021-07-13 四川农业大学 玉米基因ZmLIP2及其应用
CA3174599A1 (en) * 2020-04-09 2021-10-14 Robert Schlegl Improvements in vaccine formulations for medical use
EP4132950A1 (en) 2020-04-09 2023-02-15 Valneva Austria GmbH Compositions comprising three ospa fusion proteins for medical use
CA3230594A1 (en) * 2021-09-02 2023-03-09 Vaxcyte, Inc. Stabilization of adjuvanted vaccine compositions and their use
WO2025015077A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens
WO2025015042A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and a borrelia outer surface protein a antigen

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008625B2 (en) * 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
ATE381575T1 (de) * 2000-08-18 2008-01-15 Univ New York State Res Found Veränderte borrelia burgdorferi ospa
UA89481C2 (uk) * 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
JP2010503384A (ja) 2006-09-15 2010-02-04 インターセル アーゲー ボレリア（Ｂｏｒｒｅｌｉａ）抗原
PL2068918T5 (pl) * 2006-09-26 2024-12-02 Access To Advanced Health Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
US8466259B2 (en) 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
US8426163B2 (en) 2007-12-07 2013-04-23 National Health Research Institutes Production of lipidated proteins in E. coli
WO2011031568A2 (en) 2009-08-27 2011-03-17 Synaptic Research, Llc A NOVEL PROTEIN DELIVERY SYSTEM TO GENERATE INDUCED PLURIPOTENT STEM (iPS) CELLS OR TISSUE-SPECIFIC CELLS
AU2011252844B2 (en) 2010-05-14 2014-07-03 Baxalta GmbH Chimeric OspA genes, proteins, and methods of use thereof
PL2753352T5 (pl) 2010-09-03 2022-10-17 Valneva Austria Gmbh Izolowany polipeptyd białek toksyny a i toksyny b z c. difficile i jego zastosowania
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
US9925257B2 (en) 2011-09-23 2018-03-27 Forsyth Dental Infirmary For Children Vaccine and therapeutic delivery system
JP6304888B2 (ja) 2011-12-06 2018-04-04 ムベア カルボ テック ゲーエムベーハーＭｕｂｅａ Ｃａｒｂｏ Ｔｅｃｈ Ｇｍｂｈ 繊維強化材料製ホイールおよび対応するホイールの作製方法
EP3269386B1 (en) 2011-12-06 2022-09-14 Valneva Austria GmbH Aluminium compounds for use in therapeutics and vaccines
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
HUE043779T2 (hu) 2014-01-09 2019-09-30 Valneva Austria Gmbh Az OspA mutáns fragmensei, valamint az ezzel kapcsolatos módszerek és alkalmazások
CZ2014320A3 (cs) 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
CN108884134A (zh) 2015-12-10 2018-11-23 加拿大全国研究委员会 脂化肺炎链球菌抗原组合物、制备方法和用途
US12018054B2 (en) 2017-04-13 2024-06-25 Valneva Austria Gmbh Multivalent OspA polypeptides and methods and uses relating thereto
WO2019092002A1 (en) 2017-11-07 2019-05-16 Valneva Se Pharmaceutical compositions for treatment or prevention of viral infections
EP3972639A1 (en) 2019-05-20 2022-03-30 Valneva SE A subunit vaccine for treatment or prevention of a respiratory tract infection
KR20250107297A (ko) 2020-04-02 2025-07-11 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
CA3174599A1 (en) 2020-04-09 2021-10-14 Robert Schlegl Improvements in vaccine formulations for medical use
EP4132950A1 (en) 2020-04-09 2023-02-15 Valneva Austria GmbH Compositions comprising three ospa fusion proteins for medical use

Also Published As

Publication number Publication date
US20170107263A1 (en) 2017-04-20
SMT201800557T1 (it) 2018-11-09
HRP20181689T1 (hr) 2018-12-28
CN104487084B (zh) 2017-09-22
EP2869839B1 (en) 2018-09-05
US10544194B2 (en) 2020-01-28
US20230295245A1 (en) 2023-09-21
CY1120772T1 (el) 2019-12-11
US12195501B2 (en) 2025-01-14
KR102190981B1 (ko) 2020-12-15
KR102393038B1 (ko) 2022-04-29
WO2014006226A1 (en) 2014-01-09
PL2869839T3 (pl) 2018-12-31
EP3360568B1 (en) 2020-03-04
TR201815419T4 (tr) 2018-11-21
CN107602676A (zh) 2018-01-19
US20180327460A1 (en) 2018-11-15
JP2015522270A (ja) 2015-08-06
ES2688883T3 (es) 2018-11-07
US20150250865A1 (en) 2015-09-10
US11208439B2 (en) 2021-12-28
MX364623B (es) 2019-05-03
EA201991059A1 (ru) 2020-01-31
US20170101446A1 (en) 2017-04-13
PT2869839T (pt) 2018-11-12
HK1207982A1 (en) 2016-02-19
HK1209370A1 (en) 2016-04-01
KR20150036191A (ko) 2015-04-07
DK2869839T3 (en) 2018-10-15
KR20200141096A (ko) 2020-12-17
MX2015000013A (es) 2015-06-04
EP3360568A1 (en) 2018-08-15
MX391136B (es) 2025-03-21
US20150232517A1 (en) 2015-08-20
CN104487084A (zh) 2015-04-01
AU2017218974C1 (en) 2020-02-20
ZA201409222B (en) 2016-08-31
US8986704B2 (en) 2015-03-24
CA2876541A1 (en) 2014-01-09
EA201590162A1 (ru) 2015-06-30
JP6276258B2 (ja) 2018-02-07
AU2017218974B2 (en) 2019-05-30
CA2876541C (en) 2022-03-01
EP3689372A1 (en) 2020-08-05
EP2869839A1 (en) 2015-05-13
EP3689372B1 (en) 2026-04-29
HK1257893A1 (en) 2019-11-01
SI2869839T1 (sl) 2018-11-30
EA033007B1 (ru) 2019-08-30
AU2013285364A1 (en) 2015-01-29
HK1248244A1 (zh) 2018-10-12
US9926343B2 (en) 2018-03-27
NZ733026A (en) 2019-09-27
US11466058B2 (en) 2022-10-11
US20140010835A1 (en) 2014-01-09
RS57847B1 (sr) 2018-12-31
AU2013285364B2 (en) 2017-06-15
US20220185851A1 (en) 2022-06-16
ES2800873T3 (es) 2021-01-04
US20200239525A1 (en) 2020-07-30
CN107602676B (zh) 2021-06-04
LT2869839T (lt) 2018-11-12
HUE041286T2 (hu) 2019-05-28
AU2017218974A1 (en) 2017-09-07

Similar Documents

Publication Publication Date Title
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
NZ721015A (en) Mutant fragments of ospa and methods and uses relating thereto
MX359953B (es) Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada.
SG10201907775QA (en) Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
AU2018253544A1 (en) Methods for treating or preventing asthma by administering an IL-4R antagonist
CA2818969A1 (en) Improved n-terminal capping modules for designed ankyrin repeat proteins
SG10201907522QA (en) Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
EP4324845A3 (en) Methods and pharmaceutical composition for the treatment and the prevention of cardiomyopathy due to energy failure
NZ705370A (en) Fcγriib-specific fc region variant
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
MY167232A (en) Polypeptides binding to human complement c5
AU2011328009A8 (en) Compounds and methods for treating pain
PH12013502479A1 (en) Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
GB2496337A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
EP4414376A3 (en) Novel depsipeptide and uses thereof
MX2014010664A (es) Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso.
MD20120127A2 (en) Recombinant Koi herpesvirus (KHV), method for its production and vaccine for the prevention of a disease caused by KHV
MY178445A (en) Novel antibody binding to tfpi and composition comprising the same
IN2014DN06920A (https=)
PH12013501205A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
MX357071B (es) Medicamentos que comprenden apolipoproteína a-iv no glicosilada para el tratamiento de diabetes.
WO2013158818A3 (en) Vaccines and methods to treat lyme disease in dogs
WO2015200768A3 (en) Pharmacologic treatments of menière's disease
WO2012158639A3 (en) Recombinant fusion proteins and methods for use thereof for treatment or prevention of papillomavirus infection
TN2010000463A1 (en) Compositions and methods for preparing and using same

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2019 BY DENNEMEYER + CO.

Effective date: 20180622

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2020 BY DENNEMEYER CO.

Effective date: 20190620

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2021 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20200629

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2022 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20210629

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2023 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20220627

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2024 BY DENNEMEYER + CO. SARL

Effective date: 20230626

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2025 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20240702

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2026 BY DENNEMEYER + CO. SARL

Effective date: 20250630